Рет қаралды 1,452
In this interview with HCPLive, Stephen Harrison, MD, provides insight into the use of resmetirom for nonalcoholic steatohepatitis (NASH) with fibrosis based on data from the phase 3 MAESTRO-NASH trial ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.
An oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver, resmetirom’s safety and efficacy for adults with NASH has been demonstrated in phase 2 and 3 trials. MAESTRO-NASH, a phase 3, double-blind, randomized, placebo-controlled trial, is 1 of 18 studies in resmetirom’s clinical development program supporting the NDA for its use in adult patients with NASH and fibrosis.
Results showed NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the resmetirom 80 mg group and 29.9% of those in the resmetirom 100 mg group, compared to 9.7% of those in the placebo group (P <.001). Fibrosis improvement by at least 1 stage with no worsening of the NAFLD activity score was also superior in the resmetirom 80 mg (24.2%) and resmetirom 100 mg (25.9%) groups versus the placebo group (14.2%; P <.001).
Additionally, the change in LDL cholesterol levels from baseline to week 24 was −13.6% in the resmetirom 80 mg group and −16.3% in the resmetirom 100 mg group, as compared with 0.1% in the placebo group (P<.001).
Full articles:
www.hcplive.com/view/stephen-...
www.hcplive.com/view/stephen-...
More hepatology content:
www.hcplive.com/clinical/hepa...
#hepatology #fattyliver #NASH